

Miguel A Gonzalez-Gay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6187873/publications.pdf>

Version: 2024-02-01

612
papers

27,928
citations

3933

88
h-index

9589

142
g-index

634
all docs

634
docs citations

634
times ranked

24093
citing authors

#	ARTICLE	IF	CITATIONS
1	Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis. <i>Reumatología Clínica</i> , 2022, 18, 33-41.	0.5	4
2	Identification of a shared genetic risk locus for Kawasaki disease and immunoglobulin A vasculitis by a cross-phenotype meta-analysis. <i>Rheumatology</i> , 2022, 61, 1204-1210.	1.9	7
3	An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 539-548.	3.0	8
4	QRISK3 relation to carotid plaque is higher than that of score in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, 1408-1416.	1.9	8
5	Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 311-333.	2.4	1
6	A new immunometabolic perspective of intervertebral disc degeneration. <i>Nature Reviews Rheumatology</i> , 2022, 18, 47-60.	8.0	131
7	Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis. <i>Reumatología Clínica (English Edition)</i> , 2022, 18, 33-41.	0.3	0
8	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 768-779.	0.9	128
9	Biologic therapy in refractory neurobehavioural disease: a multicentre study of 41 patients and literature review. <i>Rheumatology</i> , 2022, 61, 4427-4436.	1.9	3
10	Intravenous methylprednisolone induces rapid improvement in non-infectious uveitis: a multicentre study of 112 patients. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 142-149.	0.8	6
11	Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 274-283.	0.8	16
12	Advances in the Treatment of Giant Cell Arteritis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1588.	2.4	11
13	Long-term survival of renal transplantation in patients with lupus nephritis: experience from a single university centre. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 581-588.	0.8	2
14	Leptin in Osteoarthritis and Rheumatoid Arthritis: Player or Bystander?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2859.	4.1	19
15	Angiogenic T Cells: Potential Biomarkers for the Early Diagnosis of Interstitial Lung Disease in Autoimmune Diseases?. <i>Biomedicines</i> , 2022, 10, 851.	3.2	3
16	Disease activity in patients with rheumatoid arthritis increases serum levels of apolipoprotein C-III. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
17	SCORE2 versus SCORE in patients with systemic lupus erythematosus. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210923.	2.7	3
18	Utility of tocilizumab in autoimmune eye diseases. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 789-799.	3.1	4

#	ARTICLE	IF	CITATIONS
19	Obesity and response to biological therapy in rheumatoid arthritis: the role of body mass index and adipose tissue cytokines.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0
20	Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies.. Clinical and Experimental Rheumatology, 2022, 40, 274-283.	0.8	0
21	Defining anti-synthetase syndrome: a systematic literature review.. Clinical and Experimental Rheumatology, 2022, 40, 309-319.	0.8	1
22	Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0
23	Alpha-Klotho protein in systemic lupus erythematosus.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0
24	Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210932.	2.7	8
25	Serum leptin concentration is associated with the attainment of clinical outcomes in patients with axial spondyloarthritis treated with TNF inhibitors. Clinical and Experimental Rheumatology, 2022, , .	0.8	2
26	The angiotensin-like protein 4, apolipoprotein C3, and lipoprotein lipase axis is disrupted in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2022, 24, 99.	3.5	7
27	Epidemiological and genetic features of anti-3-hydroxy-3-methylglutaryl-CoA reductase necrotizing myopathy: Single-center experience and literature review. European Journal of Internal Medicine, 2022, 101, 86-92.	2.2	5
28	WISP-2 modulates the induction of inflammatory mediators and cartilage catabolism in chondrocytes. Laboratory Investigation, 2022, 102, 989-999.	3.7	3
29	Treatment of migraine with monoclonal antibodies. Expert Opinion on Biological Therapy, 2022, 22, 707-716.	3.1	3
30	Key Molecules of Triglycerides Pathway Metabolism Are Disturbed in Patients With Systemic Lupus Erythematosus. Frontiers in Immunology, 2022, 13, .	4.8	5
31	Apolipoprotein C-III in patients with systemic lupus erythematosus. Arthritis Research and Therapy, 2022, 24, 104.	3.5	3
32	The role of PET/CT in the evaluation of patients with large-vessel vasculitis: useful for diagnosis but with potential limitations for follow-up. Rheumatology, 2022, 61, 4587-4589.	1.9	3
33	Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies. RMD Open, 2022, 8, e002103.	3.8	10
34	Apolipoprotein C3 Is Downregulated in Patients With Inflammatory Bowel Disease. Clinical and Translational Gastroenterology, 2022, 13, e00500.	2.5	4
35	Factors associated with atherosclerosis in radiographic and non-radiographic axial spondyloarthritis. A multicenter study on 838 patients. Seminars in Arthritis and Rheumatism, 2022, 55, 152037.	3.4	6
36	Apolipoprotein C-III is linked to the insulin resistance and beta-cell dysfunction that are present in rheumatoid arthritis. Arthritis Research and Therapy, 2022, 24, .	3.5	4

#	ARTICLE	IF	CITATIONS
37	Management of Cardiovascular Disease Risk in Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2022, 11, 3487.	2.4	4
38	Cardiovascular mortality and cardiovascular event rates in patients with inflammatory rheumatic diseases in the CARdiovascular in rheuMATology (CARMA) prospective study—results at 5 years of follow-up. <i>Rheumatology</i> , 2021, 60, 2906-2915.	1.9	15
39	Combined use of QRISK3 and SCORE as predictors of carotid plaques in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 2801-2807.	1.9	14
40	Differences in Capacity of High-Density Lipoprotein Cholesterol Efflux Between Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 1590-1596.	3.4	12
41	Higher Prevalence and Degree of Insulin Resistance in Patients With Rheumatoid Arthritis Than in Patients With Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2021, 48, 339-347.	2.0	10
42	Biologic Therapy in COVID-19. <i>Archivos De Bronconeumologia</i> , 2021, 57, 1-2.	0.8	15
43	Long-term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Behçet Disease: National Study of 103 White Patients. <i>Journal of Rheumatology</i> , 2021, 48, 741-750.	2.0	17
44	HLA association with the susceptibility to anti-synthetase syndrome. <i>Joint Bone Spine</i> , 2021, 88, 105115.	1.6	8
45	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2021, 73, 1073-1085.	5.6	81
46	Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity. <i>Rheumatology</i> , 2021, 60, 2296-2306.	1.9	10
47	Beta-cell function is disrupted in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 3826-3833.	1.9	8
48	Potential relation of cardiovascular risk factors to disease activity in patients with axial spondyloarthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110337.	2.7	5
49	Evaluation of serum omentin-1 and apelin concentrations in patients with hidradenitis suppurativa. <i>Postepy Dermatologii I Alergologii</i> , 2021, 38, 450-454.	0.9	7
50	Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110209.	2.7	7
51	Comment on: Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity: reply. <i>Rheumatology</i> , 2021, 60, e268-e269.	1.9	0
52	An Update on the Role of Leptin in the Immuno-Metabolism of Cartilage. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2411.	4.1	23
53	Predicting the risk of relapse in polymyalgia rheumatica: novel insights. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 225-232.	3.0	5
54	A Review of the Dermatological Complications of Giant Cell Arteritis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2021, Volume 14, 303-312.	1.8	7

#	ARTICLE	IF	CITATIONS
55	Monomeric C reactive protein (mCRP) regulates inflammatory responses in human and mouse chondrocytes. <i>Laboratory Investigation</i> , 2021, 101, 1550-1560.	3.7	12
56	Subclinical atherosclerotic disease in ankylosing spondylitis and non-radiographic axial spondyloarthritis. A multicenter study on 806 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 395-403.	3.4	14
57	Carotid Plaque Assessment Reclassifies Patients with Inflammatory Bowel Disease into Very-High Cardiovascular Risk. <i>Journal of Clinical Medicine</i> , 2021, 10, 1671.	2.4	8
58	Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice. <i>Journal of Rheumatology</i> , 2021, 48, 1552-1558.	2.0	3
59	Role of VEGF Polymorphisms in the Susceptibility and Severity of Interstitial Lung Disease. <i>Biomedicines</i> , 2021, 9, 458.	3.2	3
60	Atypical presentation of immunoglobulin G4-related disease as subglottic stenosis: a case-based review. <i>Rheumatology International</i> , 2021, 41, 1161-1167.	3.0	3
61	Vaspin in atherosclerotic disease and cardiovascular risk in axial spondyloarthritis: a genetic and serological study. <i>Arthritis Research and Therapy</i> , 2021, 23, 111.	3.5	7
62	Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 387-394.	3.4	13
63	<i><i>HLA-B*08</i> Identified as the Most Prominently Associated Major Histocompatibility Complex Locus for Anti-Carbamylated Protein Antibody-Positive/Anti-Cyclic Citrullinated Peptide-Negative Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i>, 2021, 73, 963-969.</i>	5.6	12
64	Rheumatoid arthritis related interstitial lung disease. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 485-497.	3.0	18
65	Disease activity influences the reclassification of rheumatoid arthritis into very high cardiovascular risk. <i>Arthritis Research and Therapy</i> , 2021, 23, 162.	3.5	13
66	Interstitial Lung Disease and Anti-Myeloperoxidase Antibodies: Not a Simple Association. <i>Journal of Clinical Medicine</i> , 2021, 10, 2548.	2.4	8
67	BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis. <i>Scientific Reports</i> , 2021, 11, 11510.	3.3	5
68	Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review. <i>Autoimmunity Reviews</i> , 2021, 20, 102830.	5.8	47
69	Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit. <i>RMD Open</i> , 2021, 7, e001724.	3.8	12
70	Endothelial Progenitor Cells: Relevant Players in the Vasculopathy and Lung Fibrosis Associated with the Presence of Interstitial Lung Disease in Systemic Sclerosis Patients. <i>Biomedicines</i> , 2021, 9, 847.	3.2	10
71	Insulin Resistance Is Not Increased in Inflammatory Bowel Disease Patients but Is Related to Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 3062.	2.4	6
72	Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis. <i>Scientific Reports</i> , 2021, 11, 16163.	3.3	1

#	ARTICLE	IF	CITATIONS
73	Imaging Tests in the Early Diagnosis of Giant Cell Arteritis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3704.	2.4	16
74	Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic. <i>Pharmaceuticals</i> , 2021, 14, 819.	3.8	12
75	Epidemiology of sarcoidosis in northern Spain, 1999-2019: A population-based study. <i>European Journal of Internal Medicine</i> , 2021, 91, 63-69.	2.2	7
76	Severe microscopic polyangiitis limited to the skin. <i>Rheumatology</i> , 2021, , .	1.9	0
77	QRISK3 Performance in the Assessment of Cardiovascular Risk in Patients with Inflammatory Bowel Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 4102.	2.4	1
78	Diagnóstico de la arteritis de células gigantes. <i>Medicina Clínica</i> , 2021, 157, 285-287.	0.6	2
79	Body Mass Index and Disease Activity in Chronic Inflammatory Rheumatic Diseases: Results of the Cardiovascular in Rheumatology (Carma) Project. <i>Journal of Clinical Medicine</i> , 2021, 10, 382.	2.4	11
80	Cranial and extracranial giant cell arteritis do not have different HLA-DRB1 and HLA-B association in Caucasian individuals. <i>Arthritis Research and Therapy</i> , 2021, 23, 268.	3.5	0
81	Moderate and High Disease Activity Predicts the Development of Carotid Plaque in Rheumatoid Arthritis Patients without Classic Cardiovascular Risk Factors: Six Years Follow-Up Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4975.	2.4	9
82	Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisyndetase syndrome. <i>Scientific Reports</i> , 2021, 11, 22574.	3.3	4
83	Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: a 3-year study of 102 cases from a single centre. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 612-620.	0.8	0
84	Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 105-114.	0.8	4
85	Evidence for uncoupling of clinical and 18-FDG activity of PET/CT scan improvement in tocilizumab-treated patients with large-vessel giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 69-75.	0.8	4
86	Intravenous methylprednisolone induces rapid improvement in non-infectious uveitis: a multicentre study of 112 patients. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	1
87	The presence of both HLA-DRB1*04:01 and HLA-B*15:01 increases the susceptibility to cranial and extracranial giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 21-26.	0.8	3
88	Tocilizumab in Behçet's disease with refractory ocular and/or neurological involvement: response according to different clinical phenotypes. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 132, 37-42.	0.8	1
89	Coexisting sarcoidosis and systemic lupus erythematosus: a case report and literature review. <i>Acta Reumatológica Portuguesa</i> , 2021, 46, 177-185.	0.2	0
90	Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0

#	ARTICLE	IF	CITATIONS
91	Amylin serum levels are upregulated in patients with systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
92	Long-term survival of renal transplantation in patients with lupus nephritis: experience from a single university centre. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
93	Evidence for uncoupling of clinical and 18-FDG activity of PET/CT scan improvement in tocilizumab-treated patients with large-vessel giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 69-75.	0.8	25
94	The presence of both HLA-DRB1[*]04:01 and HLA-B[*]15:01 increases the susceptibility to cranial and extracranial giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 21-26.	0.8	13
95	Tocilizumab in Behçet's disease with refractory ocular and/or neurological involvement: response according to different clinical phenotypes. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 37-42.	0.8	16
96	SCORE2 Assessment in the Calculation of Cardiovascular Risk in Patients with Rheumatoid Arthritis. <i>Diagnostics</i> , 2021, 11, 2363.	2.6	3
97	Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study. <i>RMD Open</i> , 2021, 7, e001925.	3.8	8
98	Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 105-114.	0.8	17
99	Apolipoprotein C3 and beta-cell dysfunction are linked in patients with systemic lupus erythematosus.. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
100	Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: a 3-year study of 102 cases from a single centre. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 612-620.	0.8	8
101	Impact of Comorbidity on Physical Function in Patients With Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics: Results From a Cross-sectional Study. <i>Arthritis Care and Research</i> , 2020, 72, 822-828.	3.4	28
102	Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. <i>Autoimmunity Reviews</i> , 2020, 19, 102429.	5.8	197
103	Positron emission tomography/computed tomography in relapsing polychondritis. <i>Rheumatology</i> , 2020, 59, 7-8.	1.9	1
104	Unmet needs in the management of cardiovascular risk in inflammatory joint diseases. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 23-36.	3.0	16
105	Smoking cessation is associated with lower disease activity and predicts cardiovascular risk reduction in rheumatoid arthritis patients. <i>Rheumatology</i> , 2020, 59, 1997-2004.	1.9	29
106	Circulating levels of adiponectin, leptin, resistin and visfatin in non-diabetics patients with hidradenitis suppurativa. <i>Archives of Dermatological Research</i> , 2020, 312, 595-600.	1.9	18
107	Association of Human Leukocyte Antigens Class II Variants with Susceptibility to Hidradenitis Suppurativa in a Caucasian Spanish Population. <i>Journal of Clinical Medicine</i> , 2020, 9, 3095.	2.4	2
108	Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 3070.	2.4	16

#	ARTICLE	IF	CITATIONS
109	Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic. <i>Dermatologic Therapy</i> , 2020, 33, e14464.	1.7	5
110	Cranial and extracranial giant cell arteritis share similar HLA-DRB1 association. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 897-901.	3.4	7
111	O31...Integrative analysis reveals a molecular stratification of systemic autoimmune diseases. , 2020, , .		1
112	Effect of cardiovascular disease on chronic inflammatory joint disease: reverse causality?. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 855-858.	3.0	0
113	Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 2816.	2.4	36
114	The Number of Traditional Cardiovascular Risk Factors Is Independently Correlated with Disease Activity in Patients with Psoriatic Arthritis. <i>Medicina (Lithuania)</i> , 2020, 56, 415.	2.0	7
115	Misperception of the Cardiovascular Risk in Patients with Rheumatoid Arthritis. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 5954.	2.6	3
116	Effects of disease activity on lipoprotein levels in patients with early arthritis: can oxidized LDL cholesterol explain the lipid paradox theory?. <i>Arthritis Research and Therapy</i> , 2020, 22, 213.	3.5	9
117	Gastrointestinal involvement in adult IGA vasculitis. <i>Rheumatology</i> , 2020, 59, 2659-2660.	1.9	1
118	Interleukin-6 receptor blockade or TNF± inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. <i>Arthritis Research and Therapy</i> , 2020, 22, 206.	3.5	20
119	Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated or Associated to Immune-Mediated Inflammatory Diseases. A Multicenter Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2608.	2.4	3
120	Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1544-1549.	0.9	173
121	Proprotein convertase subtilisin/kexin type 9 is related to disease activity and damage in patients with systemic erythematosus lupus. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2097590.	2.7	16
122	The Performance of Vascular Age in the Assessment of Cardiovascular Risk of Patients with Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2020, 9, 4065.	2.4	2
123	Endothelial Progenitor Cells as a Potential Biomarker in Interstitial Lung Disease Associated with Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2020, 9, 4098.	2.4	16
124	Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 717-723.	3.1	20
125	The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3.6-Year Prospective Study from a Referral Center of Interstitial Lung Disease and Lung Transplantation. <i>Journal of Clinical Medicine</i> , 2020, 9, 1606.	2.4	22
126	Dickkopf-3 (DKK3) Signaling in IL-1±-Challenged Chondrocytes: Involvement of the NF-±B Pathway. <i>Cartilage</i> , 2020, , 194760352093332.	2.7	7

#	ARTICLE	IF	CITATIONS
127	Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1170-1173.	0.9	115
128	Points to consider in cardiovascular disease risk management among patients with rheumatoid arthritis living in South Africa, an unequal middle income country. <i>BMC Rheumatology</i> , 2020, 4, 42.	1.6	10
129	Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 988-990.	0.9	66
130	COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain. <i>Dermatologic Therapy</i> , 2020, 33, e13961.	1.7	34
131	Impaired HDL cholesterol efflux capacity in systemic lupus erythematosus patients is related to subclinical carotid atherosclerosis. <i>Rheumatology</i> , 2020, 59, 2847-2856.	1.9	30
132	Disease Activity Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2020, 47, 1344-1353.	2.0	11
133	Prediction of cardiovascular events in rheumatoid arthritis using risk age calculations: evaluation of concordance across risk age models. <i>Arthritis Research and Therapy</i> , 2020, 22, 90.	3.5	11
134	Levels of the Novel Endogenous Antagonist of Ghrelin Receptor, Liver-Enriched Antimicrobial Peptide-2, in Patients with Rheumatoid Arthritis. <i>Nutrients</i> , 2020, 12, 1006.	4.1	17
135	Derrame pleural y pericárdico como única manifestación de enfermedad relacionada con IgG4. <i>Archivos De Bronconeumología</i> , 2020, 56, 597-599.	0.8	3
136	Carotid plaques as predictors of cardiovascular events in patients with Rheumatoid Arthritis. Results from a 5-year-prospective follow-up study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1333-1338.	3.4	31
137	Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 608-615.	3.4	31
138	Influence of MUC5B gene on antisynthetase syndrome. <i>Scientific Reports</i> , 2020, 10, 1415.	3.3	12
139	FGF23-Klotho axis in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 50-57.	0.8	3
140	Long-term survival of lung transplantation for interstitial lung disease associated with connective tissue diseases: a study of 26 cases from a referral centre. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 615-620.	0.8	4
141	Association of apolipoprotein B/apolipoprotein A1 ratio and cardiovascular events in rheumatoid arthritis: results of the CARMA study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 662-669.	0.8	1
142	Comparable effects of traditional cardiovascular risk factors on subclinical atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 917-924.	0.8	2
143	Reclassification into very-high cardiovascular risk after carotid ultrasound in patients with axial spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 724-731.	0.8	5
144	The role of a functional variant of TYK2 in vasculitides and infections. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 949-955.	0.8	2

#	ARTICLE	IF	CITATIONS
145	Influence of IL17A gene on the pathogenesis of immunoglobulin-A vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 166-170.	0.8	0
146	Giant cell arteritis: more than a cranial disease. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 15-17.	0.8	5
147	Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 112-119.	0.8	3
148	Role of IRF5 in the pathogenesis of immunoglobulin-A vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 182-187.	0.8	0
149	Anti-IL-6 therapy reduces leptin serum levels in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1201-1205.	0.8	5
150	Reply to: Comment on: Reclassification into very-high cardiovascular risk in psoriatic arthritis as well as axial spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1268.	0.8	0
151	Association between homocysteine levels and arterial stiffness in women with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 125, 92-97.	0.8	0
152	Apremilast in refractory orogenital ulcers and other manifestations of Behçet's disease. A national multicentre study of 51 cases in clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 127, 69-75.	0.8	2
153	Predictors of positive 18F-FDG PET/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 720-727.	3.4	63
154	Early large vessel systemic vasculitis in adults. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101424.	3.3	29
155	Giant cell arteritis: is the clinical spectrum of the disease changing?. <i>BMC Geriatrics</i> , 2019, 19, 200.	2.7	26
156	Leveraging Genetic Findings for Precision Medicine in Vasculitis. <i>Frontiers in Immunology</i> , 2019, 10, 1796.	4.8	7
157	Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients. <i>American Journal of Ophthalmology</i> , 2019, 200, 85-94.	3.3	81
158	Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1042-1055.	5.6	135
159	IL-6: linking chronic inflammation and vascular calcification. <i>Nature Reviews Rheumatology</i> , 2019, 15, 457-459.	8.0	42
160	Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases. <i>Arthritis and Rheumatology</i> , 2019, 71, 2081-2089.	5.6	74
161	Molecular Relationships among Obesity, Inflammation and Intervertebral Disc Degeneration: Are Adipokines the Common Link?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2030.	4.1	84
162	Treatment of giant cell arteritis. <i>Biochemical Pharmacology</i> , 2019, 165, 230-239.	4.4	15

#	ARTICLE	IF	CITATIONS
163	Treatment of polymyalgia rheumatica. <i>Biochemical Pharmacology</i> , 2019, 165, 221-229.	4.4	17
164	Adipokines: Linking metabolic syndrome, the immune system, and arthritic diseases. <i>Biochemical Pharmacology</i> , 2019, 165, 196-206.	4.4	119
165	Tocilizumab for the treatment of adult-onset Still's disease. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 273-286.	3.1	37
166	Genetic Basis of Vasculitides with Neurologic Involvement. <i>Neurologic Clinics</i> , 2019, 37, 219-234.	1.8	4
167	FRI0646...EFFECT OF LONG-TERM MEDIUM-DOSE STEROID TREATMENT ON 18F-FDG PET/CT FINDINGS TO ASSESS VASCULAR AND MUSCULOESKELETAL INVOLVEMENT IN PATIENTSWITH POLYMYALGIA REUMATICA. , 2019, , .		0
168	AB1098...COMPARISON OF THE PERFORMANCE OF CLASSIFICATION/DIAGNOSTIC CRITERIA FOR POLYMYALGIA REUMATICA. SINGLE CENTERSTUDY OF 100 PATIENTS. , 2019, , .		0
169	SAT0109...SMOKING CESSATION IN PATIENTS WITH RA IS ASSOCIATED WITH REDUCED CVD EVENT RATES AND IMPROVED LIPID PROFILES AND PREDICTS LOWER RA DISEASE ACTIVITY. , 2019, , .		0
170	FRI0038...HERPES ZOSTER IN RHEUMATOID ARTHRITIS. PROSPECTIVE SINGLE CENTER STUDY OF 390 RA PATIENTS FOR 5YEARS. , 2019, , .		0
171	OP0169...LONG-TERM SURVIVAL IN LUNG TRANSPLANTATION FOR INTERSTITIAL LUNG DISEASE ASSOCIATED WITH CONECTIVE TISSUE DISEASES. STUDY OF 26 CASES OF A SINGLE CENTER. , 2019, , .		0
172	THU0566...OCULAR FEATURES IN 381 PATIENTS WITH SYSTEMIC SARCOIDOSIS AND ITS CORRELATION WITH THE IWOS CRITERIA. STUDY IN A UNIVERSITY HOSPITAL. , 2019, , .		0
173	SAT0124...MOLECULAR CHARACTERIZATION OF THE SERUM PROFILE ASSOCIATED TO THE INCREASED CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS PATIENTS. EFFECTS OF BIOLOGICAL DRUGS.. , 2019, , .		0
174	THU0584...RHEUMATOLOGICAL IMMUNE-RELATED ADVERSE EVENTS ASSOCIATED WITH IMMUNOTHERAPY IN SOLID ORGAN TUMOR. STUDY OF 102 CASES FROM A REFERRAL SINGLE CENTER FOR LAST 4 YEARS. , 2019, , .		0
175	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. <i>Journal of Clinical Medicine</i> , 2019, 8, 2013.	2.4	118
176	Nailfold Capillaroscopy Characteristics of Antisynthetase Syndrome and Possible Clinical Associations: Results of a Multicenter International Study. <i>Journal of Rheumatology</i> , 2019, 46, 279-284.	2.0	36
177	Disease Damage Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2019, 46, 483-491.	2.0	13
178	Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 126-135.	3.4	66
179	The role of biologics in the treatment of giant cell arteritis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 65-72.	3.1	6
180	Identification of a 3' untranslated Genetic Variant of <i>RARB</i> Associated With Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 351-360.	5.6	26

#	ARTICLE	IF	CITATIONS
181	Relationship Between Insulin Sensitivity and Î²-Cell Secretion in Nondiabetic Subjects with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 229-236.	2.0	10
182	Sex and Cardiovascular Involvement in Inflammatory Joint Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2019, 56, 278-292.	6.5	13
183	Implication of CXCL5 (epithelial neutrophil-activating peptide 78) in the development of insulin resistance in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 373-379.	0.8	2
184	Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 465-473.	0.8	19
185	Incidence of first cardiovascular event in Spanish patients with inflammatory rheumatic diseases: prospective data from the CARMA project. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 731-739.	0.8	6
186	The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 694-704.	0.8	24
187	Hyperlipoproteinaemia(a) in patients with spondyloarthritis: results of the Cardiovascular in Rheumatology (CARMA) project. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 774-782.	0.8	2
188	Biomechanics, obesity, and osteoarthritis. The role of adipokines: When the levee breaks. <i>Journal of Orthopaedic Research</i> , 2018, 36, 594-604.	2.3	76
189	Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study. <i>Rheumatology</i> , 2018, 57, 856-864.	1.9	88
190	Consideration of Antisynthetase Syndrome Features in Classifying Patients as Having Idiopathic Inflammatory Myopathy: Comment on the Article by Lundberg et al. <i>Arthritis and Rheumatology</i> , 2018, 70, 975-976.	5.6	6
191	Adipokines and inflammation: is it a question of weight?. <i>British Journal of Pharmacology</i> , 2018, 175, 1569-1579.	5.4	119
192	IgA Vasculitis: Genetics and Clinical and Therapeutic Management. <i>Current Rheumatology Reports</i> , 2018, 20, 24.	4.7	44
193	Cross-phenotype analysis of ImmunoChip data identifies <i>KDM4C</i> as a relevant locus for the development of systemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 589-595.	0.9	27
194	Genetics of immunoglobulin-A vasculitis (Henoch-Schönlein purpura): An updated review. <i>Autoimmunity Reviews</i> , 2018, 17, 301-315.	5.8	72
195	New Criteria Needed for Antisynthetase Syndrome. <i>JAMA Neurology</i> , 2018, 75, 258.	9.0	13
196	Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 22-27.	3.4	123
197	Usefulness of 18F-FDG-PET/CT imaging in a patient with neurosarcoidosis. <i>Medicina Clínica</i> , 2018, 151, 464-465.	0.6	2
198	Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease. <i>Ophthalmology</i> , 2018, 125, 1444-1451.	5.2	50

#	ARTICLE	IF	CITATIONS
199	18 F-FDG PET/CT in the follow-up of large-vessel vasculitis: A study of 37 consecutive patients. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 530-537.	3.4	45
200	Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 48-54.	0.9	194
201	A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility. <i>PLoS ONE</i> , 2018, 13, e0209343.	2.5	3
202	Meta-analysis of ImmunoChip data of four autoimmune diseases reveals novel single-disease and cross-phenotype associations. <i>Genome Medicine</i> , 2018, 10, 97.	8.2	73
203	Anakinra for the treatment of adult-onset Still's disease. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 979-992.	3.0	23
204	Detection of high cardiovascular risk patients with ankylosing spondylitis based on the assessment of abdominal aortic calcium as compared to carotid ultrasound. <i>Arthritis Research and Therapy</i> , 2018, 20, 195.	3.5	2
205	Association of a rare variant of the TNFSF13B gene with susceptibility to Rheumatoid Arthritis and Systemic Lupus Erythematosus. <i>Scientific Reports</i> , 2018, 8, 8195.	3.3	17
206	Rituximab in Takayasu arteritis: an unmet hope. <i>Rheumatology</i> , 2018, 57, 1133-1134.	1.9	4
207	Relative Risk Chart Score for the Assessment of the Cardiovascular Risk in Young Patients with Ankylosing Spondylitis. <i>International Journal of Rheumatology</i> , 2018, 2018, 1-6.	1.6	5
208	Obesity, Fat Mass and Immune System: Role for Leptin. <i>Frontiers in Physiology</i> , 2018, 9, 640.	2.8	284
209	Drug therapies for polymyalgia rheumatica: a pharmacotherapeutic update. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1235-1244.	1.8	6
210	Current and emerging diagnosis tools and therapeutics for giant cell arteritis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 593-605.	3.0	17
211	Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrhumdis-2017-212368.	0.9	24
212	Carotid ultrasound is useful for the cardiovascular risk stratification in patients with hidradenitis suppurativa. <i>PLoS ONE</i> , 2018, 13, e0190568.	2.5	9
213	Inflammatory Arthritis and Heart Disease. <i>Current Pharmaceutical Design</i> , 2018, 24, 262-280.	1.9	22
214	Molecular imaging in large vessel vasculitis has come to stay. <i>Annals of Translational Medicine</i> , 2018, 6, S2-S2.	1.7	1
215	Timing of onset affects arthritis presentation pattern in antisynthetase syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 44-49.	0.8	30
216	Cardiovascular risk stratification in axial spondyloarthritis: carotid ultrasound is more sensitive than coronary artery calcification score to detect high-cardiovascular risk axial spondyloarthritis patients. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 73-80.	0.8	16

#	ARTICLE	IF	CITATIONS
217	Implication of osteoprotegerin and sclerostin in axial spondyloarthritis cardiovascular disease: study of 163 Spanish patients. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 302-309.	0.8	5
218	Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 652-657.	0.8	12
219	Amylin in the insulin resistance of patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 421-427.	0.8	2
220	Subclinical aortitis after starting nivolumab in a patient with metastatic melanoma. A case of drug-associated aortitis?. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 111, 171.	0.8	3
221	Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 71-80.	6.5	60
222	Respuesta. <i>Medicina Clínica</i> , 2017, 148, e15-e16.	0.6	0
223	Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study. <i>Autoimmunity Reviews</i> , 2017, 16, 253-257.	5.8	46
224	Clinical association between Kikuchi's disease and systemic lupus erythematosus: A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 46-52.	3.4	39
225	Analysis of the common genetic component of large-vessel vasculitides through a meta-immunochip strategy. <i>Scientific Reports</i> , 2017, 7, 43953.	3.3	52
226	A combined large-scale meta-analysis identifies <i>COG6</i> as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 286-294.	0.9	58
227	High triglycerides and low high-density lipoprotein cholesterol lipid profile in rheumatoid arthritis: A potential link among inflammation, oxidative status, and dysfunctional high-density lipoprotein. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1043-1054.e2.	1.5	35
228	HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis. <i>Arthritis Research and Therapy</i> , 2017, 19, 113.	3.5	39
229	Clinical spectrum time course of interstitial pneumonia with autoimmune features in patients positive for antisynthetase antibodies. <i>Respiratory Medicine</i> , 2017, 132, 265-266.	2.9	34
230	Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMATology study project. <i>Journal of Clinical Lipidology</i> , 2017, 11, 749-756.e3.	1.5	30
231	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	6.2	78
232	NSAIDs and cardiovascular risk in arthritis. <i>Nature Reviews Cardiology</i> , 2017, 14, 69-70.	13.7	13
233	Leptin in the interplay of inflammation, metabolism and immune system disorders. <i>Nature Reviews Rheumatology</i> , 2017, 13, 100-109.	8.0	371
234	Polymyalgia rheumatica. <i>Lancet</i> , 2017, 390, 1700-1712.	13.7	196

#	ARTICLE	IF	CITATIONS
235	A genome-wide association study suggests the HLA Class II region as the major susceptibility locus for IgA vasculitis. <i>Scientific Reports</i> , 2017, 7, 5088.	3.3	44
236	Efficacy of Anti-IL6-Receptor Tocilizumab in Refractory Cystoid Macular Edema of Birdshot Retinochoroidopathy Report of Two Cases and Literature Review. <i>Ocular Immunology and Inflammation</i> , 2017, 25, 609-614.	1.8	33
237	Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients. <i>Arthritis and Rheumatology</i> , 2017, 69, 668-675.	5.6	129
238	Serum Levels of Anti-PON1 and Anti-HDL Antibodies as Potential Biomarkers of Premature Atherosclerosis in Systemic Lupus Erythematosus. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2194-2206.	3.4	29
239	Incretins in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 229.	3.5	12
240	Henoch-Schönlein purpura (IgA vasculitis): the paradox of the different incidence and clinical spectrum in children and adults. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 3-4.	0.8	5
241	Insulin resistance in systemic lupus erythematosus patients: contributing factors and relationship with subclinical atherosclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 885-892.	0.8	14
242	Association of Trabecular Bone Score with Inflammation and Adiposity in Patients with Psoriasis: Effect of Adalimumab Therapy. <i>Journal of Osteoporosis</i> , 2016, 2016, 1-6.	0.5	13
243	Asymmetric dimethylarginine but not osteoprotegerin correlates with disease severity in patients with moderate-to-severe psoriasis undergoing anti-tumor necrosis factor therapy. <i>Journal of Dermatology</i> , 2016, 43, 389-394.	1.2	11
244	Cardiovascular risk factor assessment: still an unmet need in chronic inflammatory diseases. <i>Heart</i> , 2016, 102, 1937-1939.	2.9	9
245	Additional proposals to reduce comorbidity in patients with chronic inflammatory rheumatic diseases: comment on "Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative" by Baillet et al. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e55-e55.	0.9	2
246	Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 95-101.	3.4	77
247	Vitamina D y enfermedades reumáticas. <i>Reumatología Clínica</i> , 2016, 12, 356-357.	0.5	0
248	Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 71-80.	3.4	98
249	Adult-onset Still's disease: Advances in the treatment. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 222-238.	3.3	91
250	Managing of giant cell arteritis and polymyalgia rheumatica. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 1133-1144.	0.8	6
251	Antibodies to paraoxonase 1 are associated with oxidant status and endothelial activation in rheumatoid arthritis. <i>Clinical Science</i> , 2016, 130, 1889-1899.	4.3	16
252	Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers. <i>Autoimmunity Reviews</i> , 2016, 15, 1013-1030.	5.8	107

#	ARTICLE	IF	CITATIONS
253	Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 261-271.	3.4	118
254	Cardiovascular disease in inflammatory rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 851-869.	3.3	95
255	Giant Cell Arteritis: Visual Loss Is Our Major Concern. <i>Journal of Rheumatology</i> , 2016, 43, 1458-1461.	2.0	41
256	Relapses in patients with Henoch-Schönlein purpura. <i>Medicine (United States)</i> , 2016, 95, e4217.	1.0	63
257	Paraoxonase 1 Activity Is Modulated by the rs662 Polymorphism and IgG Anti-High-Density Lipoprotein Antibodies in Patients With Rheumatoid Arthritis: Potential Implications for Cardiovascular Disease. <i>Arthritis and Rheumatology</i> , 2016, 68, 1367-1376.	5.6	29
258	Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review. <i>Rheumatology International</i> , 2016, 36, 1043-1063.	3.0	36
259	Increased prevalence of subclinical atherosclerosis in patients with hidradenitis suppurativa (HS). <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 329-335.	1.2	45
260	Why is Rheumatoid Arthritis Mortality Still High Despite the Advent of New Therapies? Comment on the Article by Widdifield et al. <i>Arthritis Care and Research</i> , 2016, 68, 726-727.	3.4	2
261	Anti-tumor necrosis factor-alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6-month prospective study. <i>Journal of Dermatology</i> , 2016, 43, 1267-1272.	1.2	51
262	The Framingham Score and the Systematic Coronary Risk Evaluation at Low Cutoff Values Are Useful Surrogate Markers of High-risk Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 486-494.	2.0	19
263	Gene polymorphisms and therapy in rheumatoid arthritis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 225-229.	3.3	7
264	Vitamin D receptor GATG haplotype association with atherosclerotic disease in patients with rheumatoid arthritis. <i>Atherosclerosis</i> , 2016, 245, 139-142.	0.8	11
265	Systemic and cerebral endothelial dysfunction in chronic migraine. A case-control study with an active comparator. <i>Cephalalgia</i> , 2016, 36, 552-560.	3.9	35
266	New insights into the pathogenesis of giant cell arteritis and hopes for the clinic. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 57-66.	3.0	18
267	Subclinical atherosclerosis is not increased in patients with non-radiographic axial spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 159-60.	0.8	4
268	The Spanish version of the 2010 American College of Rheumatology Preliminary Diagnostic Criteria for fibromyalgia: reliability and validity assessment. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S55-8.	0.8	9
269	Interleukin 1 beta (IL1 β) rs16944 genetic variant as a genetic marker of severe renal manifestations and renal sequelae in Henoch-Schönlein purpura. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S84-8.	0.8	12
270	Serum cathepsin S and cystatin C: relationship to subclinical carotid atherosclerosis in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 230-5.	0.8	7

#	ARTICLE	IF	CITATIONS
271	Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S44-53.	0.8	32
272	Histopathologic differences between cutaneous vasculitis associated with severe bacterial infection and cutaneous vasculitis secondary to other causes: study of 52 patients. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S93-7.	0.8	1
273	The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S34-S40.	0.8	10
274	Validation of the Spanish version of the fibromyalgia rapid screening tool to detect fibromyalgia in primary care health centres. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S125-8.	0.8	2
275	LILRA3 deficiency is not involved in the giant cell arteritis and systemic sclerosis predisposition. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 208-209.	0.8	0
276	Carotid ultrasound in the cardiovascular risk stratification of patients with ankylosing spondylitis: results of a population-based study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 885-892.	0.8	12
277	Proprotein convertase subtilisin/kexin type 9 in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 1013-1019.	0.8	9
278	Vitamin D deficiency in chronic inflammatory rheumatic diseases: results of the cardiovascular in rheumatology [CARMA] study. <i>Arthritis Research and Therapy</i> , 2015, 17, 211.	3.5	25
279	Refractory highly disfiguring lupus pernio: a dramatic and prolonged response to infliximab. <i>International Journal of Dermatology</i> , 2015, 54, e321-2.	1.0	6
280	Is the Homeostatic Model Assessment of Insulin Resistance a Poor Predictor of Cardiovascular Disease in Rheumatoid Arthritis? Comment on the Article by Giles et al. <i>Arthritis and Rheumatology</i> , 2015, 67, 2548-2550.	5.6	1
281	Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome. <i>Medicine (United States)</i> , 2015, 94, e1144.	1.0	133
282	Kidney Function, Endothelial Activation and Atherosclerosis in Black and White Africans with Rheumatoid Arthritis. <i>PLoS ONE</i> , 2015, 10, e0121693.	2.5	14
283	Lack of Association between JAK3 Gene Polymorphisms and Cardiovascular Disease in Spanish Patients with Rheumatoid Arthritis. <i>BioMed Research International</i> , 2015, 2015, 1-11.	1.9	9
284	Enhanced Cardiovascular Risk in Rheumatoid Arthritis: Elucidation, Assessment, and Management. <i>BioMed Research International</i> , 2015, 2015, 1-3.	1.9	5
285	Genetics of vasculitis. <i>Current Opinion in Rheumatology</i> , 2015, 27, 10-17.	4.3	47
286	Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. <i>Nature Communications</i> , 2015, 6, 7146.	12.8	220
287	Biologic therapy in ANCA-negative vasculitis. <i>International Immunopharmacology</i> , 2015, 27, 213-219.	3.8	15
288	Association of HLA-B*41:02 with Henoch-Schönlein Purpura (IgA Vasculitis) in Spanish individuals irrespective of the HLA-DRB1 status. <i>Arthritis Research and Therapy</i> , 2015, 17, 102.	3.5	33

#	ARTICLE	IF	CITATIONS
289	Isolated pulmonary vasculitis: Case report and literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 514-517.	3.4	12
290	Identification of secreted phosphoprotein 1 gene as a new rheumatoid arthritis susceptibility gene. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e19-e19.	0.9	24
291	Giant Cell Arteritis and Polymyalgia Rheumatica: an Update. <i>Current Rheumatology Reports</i> , 2015, 17, 6.	4.7	54
292	The search for improvement in the sensitivity of temporal artery biopsy in giant cell arteritis. <i>Rheumatology</i> , 2015, 54, 379-380.	1.9	3
293	High-density genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid arthritis risk loci. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e13-e13.	0.9	100
294	Brief Report: Association of HLA-DRB1*01 With IgA Vasculitis (Henoch-Schönlein). <i>Arthritis and Rheumatology</i> , 2015, 67, 823-827.	5.6	35
295	Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 717-723.	3.4	114
296	Sex disparities in systemic lupus erythematosus in Northwestern Spain are not due to ethnic diversity. <i>Rheumatology International</i> , 2015, 35, 939-940.	3.0	0
297	A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e15-e15.	0.9	62
298	Cardiovascular risk assessment in rheumatoid arthritis: What goals should be achieved?. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, e20-e21.	3.4	0
299	Anti-TNF- α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients. <i>Rheumatology International</i> , 2015, 35, 2069-2078.	3.0	25
300	Genetic risk scores and number of autoantibodies in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 762-768.	0.9	14
301	Anti-TNF- α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 361-368.	3.4	78
302	Carotid artery plaque in women with rheumatoid arthritis and low estimated cardiovascular disease risk: a cross-sectional study. <i>Arthritis Research and Therapy</i> , 2015, 17, 55.	3.5	29
303	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	6.2	144
304	Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 618-626.	3.4	94
305	Role of PTPN22 and CSK gene polymorphisms as predictors of susceptibility and clinical heterogeneity in patients with Henoch-Schönlein purpura (IgA vasculitis). <i>Arthritis Research and Therapy</i> , 2015, 17, 286.	3.5	11
306	Single-organ cutaneous small-vessel vasculitis according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides: a study of 60 patients from a series of 766 cutaneous vasculitis cases. <i>Rheumatology</i> , 2015, 54, 77-82.	1.9	42

#	ARTICLE	IF	CITATIONS
307	Osteoprotegerin Concentrations Relate Independently to Established Cardiovascular Disease in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 39-45.	2.0	26
308	Relationship between endothelial dysfunction and osteoprotegerin, vitamin D, and bone mineral density in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 241-9.	0.8	6
309	TNF-related apoptosis-inducing ligand and cardiovascular disease in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 491-7.	0.8	6
310	Atherosclerotic disease in axial spondyloarthritis: increased frequency of carotid plaques. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 315-20.	0.8	19
311	Relationship of abdominal adiposity and body composition with endothelial dysfunction in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 516-23.	0.8	7
312	Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S31-5.	0.8	4
313	Epistatic Interaction of ERAP1 and HLA-B in Behçet Disease: A Replication Study in the Spanish Population. <i>PLoS ONE</i> , 2014, 9, e102100.	2.5	30
314	Autoimmune Rheumatic Diseases. <i>BioMed Research International</i> , 2014, 2014, 1-3.	1.9	4
315	Rheumatoid Arthritis: Genetic Variants as Biomarkers of Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2014, 21, 182-201.	1.9	15
316	Retinol-binding Protein 4 in Rheumatoid Arthritis-related Insulin Resistance and β -cell Function. <i>Journal of Rheumatology</i> , 2014, 41, 658-665.	2.0	12
317	Patients with Ankylosing Spondylitis and Low Disease Activity because of Anti-TNF-Alpha Therapy Have Higher TRAIL Levels Than Controls: A Potential Compensatory Effect. <i>Mediators of Inflammation</i> , 2014, 2014, 1-6.	3.0	8
318	Golimumab as Rescue Therapy for Refractory Immune-Mediated Uveitis: A Three-Center Experience. <i>Mediators of Inflammation</i> , 2014, 2014, 1-5.	3.0	54
319	Lack of Association between ABO, PPAP2B, ADAMST7, PIK3CG, and EDNRA and Carotid Intima-Media Thickness, Carotid Plaques, and Cardiovascular Disease in Patients with Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2014, 2014, 1-6.	3.0	23
320	Adipokines, Biomarkers of Endothelial Activation, and Metabolic Syndrome in Patients with Ankylosing Spondylitis. <i>BioMed Research International</i> , 2014, 2014, 1-11.	1.9	33
321	IGF-1 and ADMA Levels Are Inversely Correlated in Nondiabetic Ankylosing Spondylitis Patients Undergoing Anti-TNF-Alpha Therapy. <i>BioMed Research International</i> , 2014, 2014, 1-6.	1.9	5
322	Urticarial Vasculitis in Northern Spain. <i>Medicine (United States)</i> , 2014, 93, 53-60.	1.0	46
323	Independent Relationship of Osteoprotegerin Concentrations with Endothelial Activation and Carotid Atherosclerosis in Patients with Severe Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 429-436.	2.0	32
324	Sex differences in patients with systemic lupus erythematosus from Northwest Spain. <i>Rheumatology International</i> , 2014, 34, 11-24.	3.0	32

#	ARTICLE	IF	CITATIONS
325	Short-term improvement following dry needle stimulation of tender points in fibromyalgia. <i>Rheumatology International</i> , 2014, 34, 861-866.	3.0	40
326	Brucellosis is not only responsible for monoarthritis but it is also associated with other osteoarticular complications. <i>Rheumatology International</i> , 2014, 34, 133-133.	3.0	2
327	Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: Scientific evidence and expert opinion. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 1-8.	3.4	66
328	Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis?. <i>Rheumatology</i> , 2014, 53, 1108-1119.	1.9	98
329	Response to Adipokines, inflammation, insulin resistance, and carotid atherosclerosis in patients with rheumatoid arthritis™. <i>Arthritis Research and Therapy</i> , 2014, 16, 401.	3.5	1
330	Genetic component of giant cell arteritis. <i>Rheumatology</i> , 2014, 53, 6-18.	1.9	83
331	Genetics of rheumatoid arthritis contributes to biology and drug discovery. <i>Nature</i> , 2014, 506, 376-381.	27.8	1,974
332	Investigation of aPON1gene polymorphism (rs662 polymorphism) as predictor of subclinical atherosclerosis in patients with rheumatoid arthritis: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1749-1750.	0.9	11
333	Rheumatoid arthritis and metabolic syndrome. <i>Nature Reviews Rheumatology</i> , 2014, 10, 691-696.	8.0	154
334	Drug-associated Cutaneous Vasculitis: Study of 239 Patients from a Single Referral Center. <i>Journal of Rheumatology</i> , 2014, 41, 2201-2207.	2.0	32
335	Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1281-1283.	0.9	73
336	Investigations into Audiovestibular Manifestations in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2018-2026.	2.0	18
337	Antitumour necrosis factor ± treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 941-943.	0.9	14
338	The influence of inflammation in the development of subclinical atherosclerosis in psoriatic arthritis: comment on "Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review"™ by Jamnitski <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e27-e27.	0.9	5
339	Anti-TNF-Á therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients. <i>Rheumatology</i> , 2014, 53, 2223-2231.	1.9	109
340	Fine Mapping Seronegative and Seropositive Rheumatoid Arthritis to Shared and Distinct HLA Alleles by Adjusting for the Effects of Heterogeneity. <i>American Journal of Human Genetics</i> , 2014, 94, 522-532.	6.2	156
341	ImmunoChip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. <i>American Journal of Human Genetics</i> , 2014, 94, 47-61.	6.2	182
342	Autoantibodies and biomarkers of endothelial cell activation in atherosclerosis. <i>Vasa - European Journal of Vascular Medicine</i> , 2014, 43, 83-85.	1.4	5

#	ARTICLE	IF	CITATIONS
343	GIMAP and Behçet disease: no association in the European population: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1433-1434.	0.9	17
344	Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 722-727.	0.9	190
345	Efficacy of Tocilizumab in Conventional Treatment-Refractory Adult-Onset Still's Disease: Multicenter Retrospective Open-Label Study of Thirty-Four Patients. <i>Arthritis and Rheumatology</i> , 2014, 66, 1659-1665.	5.6	115
346	Cardiovascular risk assessment according to a national calibrated score risk index in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. <i>Joint Bone Spine</i> , 2014, 81, 164-168.	1.6	11
347	Interferon regulatory factor 5 genetic variants are associated with cardiovascular disease in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2014, 16, R146.	3.5	19
348	Henoch-Schönlein Purpura in Northern Spain. <i>Medicine (United States)</i> , 2014, 93, 106-113.	1.0	117
349	Osteoprotegerin CGA Haplotype Protection against Cerebrovascular Complications in Anti-CCP Negative Patients with Rheumatoid Arthritis. <i>PLoS ONE</i> , 2014, 9, e106823.	2.5	10
350	Analysis of Ancestral and Functionally Relevant CD5 Variants in Systemic Lupus Erythematosus Patients. <i>PLoS ONE</i> , 2014, 9, e113090.	2.5	15
351	A Candidate Gene Approach Identifies an IL33 Genetic Variant as a Novel Genetic Risk Factor for GCA. <i>PLoS ONE</i> , 2014, 9, e113476.	2.5	17
352	Tocilizumab in refractory aortitis: study on 16 patients and literature review. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, S79-89.	0.8	55
353	Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, S54-7.	0.8	37
354	Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: a retrospective study of three cases from a single centre and literature review. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 864-8.	0.8	18
355	Impaired beta cell function is present in nondiabetic rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2013, 15, R17.	3.5	20
356	Cutaneous Vasculitis: A Rheumatologist Perspective. <i>Current Allergy and Asthma Reports</i> , 2013, 13, 545-554.	5.3	14
357	Short-term efficacy of topical capsaicin therapy in severely affected fibromyalgia patients. <i>Rheumatology International</i> , 2013, 33, 2665-2670.	3.0	36
358	SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2013, 15, R91.	3.5	40
359	The ZC3HC1 rs11556924 polymorphism is associated with increased carotid intima-media thickness in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2013, 15, R152.	3.5	26
360	Influence of the STAT3 genetic variants in the susceptibility to psoriatic arthritis and Behçet's disease. <i>Human Immunology</i> , 2013, 74, 230-233.	2.4	30

#	ARTICLE	IF	CITATIONS
361	Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. <i>Nature Genetics</i> , 2013, 45, 730-738.	21.4	699
362	Evidence of association of the <i>NLRP1</i> gene with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 628-630.	0.9	23
363	Cold Hands Associated with Scleroderma. <i>New England Journal of Medicine</i> , 2013, 369, 1638-1638.	27.0	0
364	Marked Independent Relationship between Circulating Interleukin-6 Concentrations and Endothelial Activation in Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2013, 2013, 1-10.	3.0	23
365	New insight on the Xq28 association with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 2032-2038.	0.9	52
366	Etanercept-induced hypertriglyceridemia during the treatment of recurrent aphthous stomatitis. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2013, 79, 432.	0.6	3
367	Metabolic Syndrome in Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2013, 2013, 1-11.	3.0	77
368	Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1764-1770.	0.9	123
369	Confirmation of <i>TNIP1</i> but not <i>RHOB</i> and <i>PSORS1C1</i> as systemic sclerosis risk factors in a large independent replication study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 602-607.	0.9	56
370	Antitumour necrosis factor- α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1265-1267.	0.9	10
371	Implication of <i>IL-2/IL-21</i> region in systemic sclerosis genetic susceptibility. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1233-1238.	0.9	30
372	A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. <i>Human Molecular Genetics</i> , 2013, 22, 4021-4029.	2.9	104
373	Cholesteryl Ester Transfer Protein in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 1040-1047.	2.0	18
374	Disparate results in studies of adalimumab in the treatment of hidradenitis suppurativa: comment on the article by Amano <i>et al</i> . <i>International Journal of Dermatology</i> , 2013, 52, 380-381.	1.0	1
375	<i>CARD8</i> rs2043211 (p.C10X) Polymorphism Is Not Associated with Disease Susceptibility or Cardiovascular Events in Spanish Rheumatoid Arthritis Patients. <i>DNA and Cell Biology</i> , 2013, 32, 28-33.	1.9	29
376	HLA and non-HLA genes in Behçet's disease: a multicentric study in the Spanish population. <i>Arthritis Research and Therapy</i> , 2013, 15, R145.	3.5	50
377	The Spectrum of Paraneoplastic Cutaneous Vasculitis in a Defined Population. <i>Medicine (United States)</i> 94(1):1-10. 10.7843/14 rgBT /Overlock 1/55	1.0	55
378	Association of CD247 Polymorphisms with Rheumatoid Arthritis: A Replication Study and a Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e68295.	2.5	19

#	ARTICLE	IF	CITATIONS
379	SMAD3 rs17228212 Gene Polymorphism Is Associated with Reduced Risk to Cerebrovascular Accidents and Subclinical Atherosclerosis in Anti-CCP Negative Spanish Rheumatoid Arthritis Patients. PLoS ONE, 2013, 8, e77695.	2.5	12
380	Evidence of New Risk Genetic Factor to Systemic Lupus Erythematosus: The UBASH3A Gene. PLoS ONE, 2013, 8, e60646.	2.5	27
381	Epistatic Interaction between BANK1 and BLK in Rheumatoid Arthritis: Results from a Large Trans-Ethnic Meta-Analysis. PLoS ONE, 2013, 8, e61044.	2.5	24
382	Heme oxygenase-1 promoter polymorphisms do not influence susceptibility to systemic sclerosis and its clinical phenotypes. Clinical and Experimental Rheumatology, 2013, 31, 186.	0.8	0
383	Atherosclerosis in Rheumatoid Arthritis. Mediators of Inflammation, 2012, 2012, 1-2.	3.0	7
384	Carotid ultrasound in the cardiovascular risk stratification of patients with rheumatoid arthritis: when and for whom?. Annals of the Rheumatic Diseases, 2012, 71, 796-798.	0.9	34
385	Genetic Markers of Cardiovascular Disease in Rheumatoid Arthritis. Mediators of Inflammation, 2012, 2012, 1-14.	3.0	33
386	Anti-TNF-Alpha-Adalimumab Therapy Is Associated with Persistent Improvement of Endothelial Function without Progression of Carotid Intima-Media Wall Thickness in Patients with Rheumatoid Arthritis Refractory to Conventional Therapy. Mediators of Inflammation, 2012, 2012, 1-8.	3.0	50
387	Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nature Reviews Rheumatology, 2012, 8, 224-234.	8.0	118
388	Obesity impairs efficacy of anti-TNF therapy in patients with RA. Nature Reviews Rheumatology, 2012, 8, 641-642.	8.0	20
389	Evaluation of a Shared Autoimmune Disease-associated Polymorphism of TRAF6 in Systemic Sclerosis and Giant Cell Arteritis. Journal of Rheumatology, 2012, 39, 1275-1279.	2.0	3
390	Replication of association of the interleukin 23 receptor rs1343151 variant with rheumatoid arthritis in Caucasian sample sets. Annals of the Rheumatic Diseases, 2012, 71, 155-157.	0.9	13
391	Lack of Association Between TLR4 rs4986790 Polymorphism and Risk of Cardiovascular Disease in Patients with Rheumatoid Arthritis. DNA and Cell Biology, 2012, 31, 1214-1220.	1.9	21
392	Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. Human Molecular Genetics, 2012, 21, 2825-2835.	2.9	98
393	Interstitial Keratitis Secondary to Severe Hidradenitis Suppurativa Responding to Adalimumab. Cornea, 2012, 31, 206-206.	1.7	2
394	Particle Repositioning Maneuver Versus Brandt-Daroff Exercise for Treatment of Unilateral Idiopathic BPPV of the Posterior Semicircular Canal. Otology and Neurotology, 2012, 33, 1401-1407.	1.3	62
395	High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nature Genetics, 2012, 44, 1336-1340.	21.4	558
396	Association Study of MIA3 rs17465637 Polymorphism with Cardiovascular Disease in Rheumatoid Arthritis Patients. DNA and Cell Biology, 2012, 31, 1412-1417.	1.9	14

#	ARTICLE	IF	CITATIONS
397	Influence of the <i>IL6</i> Gene in Susceptibility to Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2012, 39, 2294-2302.	2.0	34
398	Polymorphisms in the Interleukin 4, Interleukin 13, and Corresponding Receptor Genes Are Not Associated with Systemic Sclerosis and Do Not Influence Gene Expression. <i>Journal of Rheumatology</i> , 2012, 39, 112-118.	2.0	8
399	Analysis of the Interferon Gamma (rs2430561, +874T/A) Functional Gene Variant in Relation to the Presence of Cardiovascular Events in Rheumatoid Arthritis. <i>PLoS ONE</i> , 2012, 7, e47166.	2.5	12
400	NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis. <i>Atherosclerosis</i> , 2012, 224, 426-429.	0.8	72
401	Successful effect of tocilizumab in anti-TNF- α -induced palmoplantar pustulosis in rheumatoid arthritis. <i>Joint Bone Spine</i> , 2012, 79, 510-513.	1.6	22
402	Association study of BAK1 gene polymorphisms in Spanish rheumatoid arthritis and systemic lupus erythematosus cohorts. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 314-316.	0.9	2
403	Novel association of acid phosphatase locus 1* C allele with systemic lupus erythematosus. <i>Human Immunology</i> , 2012, 73, 107-110.	2.4	9
404	Lack of association between the CXCL12 rs501120 polymorphism and cardiovascular disease in Spanish patients with rheumatoid arthritis. <i>Human Immunology</i> , 2012, 73, 543-546.	2.4	5
405	Lack of association between flow-mediated endothelium-dependent vasodilatation and biomarkers of endothelial dysfunction in patients with severe rheumatoid arthritis. <i>Rheumatology International</i> , 2012, 32, 4071-4072.	3.0	2
406	KCNA5 gene is not confirmed as a systemic sclerosis-related pulmonary arterial hypertension genetic susceptibility factor. <i>Arthritis Research and Therapy</i> , 2012, 14, R273.	3.5	10
407	Inflammation, endothelial function and atherosclerosis in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2012, 14, 122.	3.5	18
408	Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2012, 14, R154.	3.5	11
409	Implication of new atherosclerotic carotid plaques in the cardiovascular outcome of patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2012, 14, 105.	3.5	1
410	The lp13.3 genomic region -rs599839- is associated with endothelial dysfunction in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2012, 14, R42.	3.5	12
411	A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis. <i>Arthritis Research and Therapy</i> , 2012, 14, R85.	3.5	32
412	NPSR1 Gene Is Associated with Reduced Risk of Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 1166-1170.	2.0	10
413	Efficacy of a multidisciplinary treatment program in patients with severe fibromyalgia. <i>Rheumatology International</i> , 2012, 32, 2497-2502.	3.0	18
414	Assessment of cardiovascular risk in rheumatoid arthritis: impact of the new EULAR recommendations on the score cardiovascular risk index. <i>Clinical Rheumatology</i> , 2012, 31, 35-39.	2.2	30

#	ARTICLE	IF	CITATIONS
415	Carotid ultrasound as predictor of atherosclerosis in rheumatoid arthritis. <i>Vasa - European Journal of Vascular Medicine</i> , 2012, 41, 311-312.	1.4	1
416	Study of Association of CD40-CD154 Gene Polymorphisms with Disease Susceptibility and Cardiovascular Risk in Spanish Rheumatoid Arthritis Patients. <i>PLoS ONE</i> , 2012, 7, e49214.	2.5	36
417	Autoimmune disease-associated CD226 gene variants are not involved in giant cell arteritis susceptibility in the Spanish population. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S29-33.	0.8	4
418	Bone mass and vitamin D in patients with systemic sclerosis from two Spanish regions. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 905-11.	0.8	14
419	Lack of association between carotid intima-media wall thickness and carotid plaques and markers of endothelial cell activation in rheumatoid arthritis patients undergoing anti-TNF therapy. <i>Acta Reumatológica Portuguesa</i> , 2012, 37, 155-9.	0.2	4
420	Analysis of the <i>REL</i> polymorphism rs13031237 in autoimmune diseases. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 711-712.	0.9	18
421	CCR5 Δ 32 variant and cardiovascular disease in patients with rheumatoid arthritis: a cohort study. <i>Arthritis Research and Therapy</i> , 2011, 13, R133.	3.5	40
422	Association of acid phosphatase locus 1* <i>C</i> allele with the risk of cardiovascular events in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2011, 13, R116.	3.5	21
423	Correlation between endothelial function and carotid atherosclerosis in rheumatoid arthritis patients with long-standing disease. <i>Arthritis Research and Therapy</i> , 2011, 13, R101.	3.5	117
424	Response to 'Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomized study over 21 months'. <i>Arthritis Research and Therapy</i> , 2011, 13, 404.	3.5	2
425	Role of the CCR5 Δ 32/CCR5 polymorphism in biopsy-proven giant cell arteritis. <i>Human Immunology</i> , 2011, 72, 458-461.	2.4	9
426	No evidence of association of the KLF12 gene with rheumatoid arthritis in Spanish and Dutch cohorts and a meta-analysis of published data. <i>Human Immunology</i> , 2011, 72, 779-782.	2.4	3
427	TNFA Δ 308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. <i>Atherosclerosis</i> , 2011, 216, 125-130.	0.8	116
428	Lack of association between IL6 single nucleotide polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis. <i>Atherosclerosis</i> , 2011, 219, 655-658.	0.8	21
429	Audiovestibular Manifestations in Patients With Ankylosing Spondylitis. <i>Medicine (United States)</i> , 2011, 90, 99-109.	1.0	30
430	An Audit of the Variability of Diagnosis and Management of Gout in the Rheumatology Setting. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 349-355.	0.9	41
431	Benign Paroxysmal Positional Vertigo and Clinical Test of Sensory Interaction and Balance in Ankylosing Spondylitis. <i>Otology and Neurotology</i> , 2011, 32, 278-283.	1.3	11
432	Systemic Lupus Erythematosus in Northwestern Spain. <i>Medicine (United States)</i> , 2011, 90, 350-358.	1.0	54

#	ARTICLE	IF	CITATIONS
433	Carotid Intima Media Thickness in Rheumatoid Arthritis as Compared to Control Subjects: A Meta-Analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 40, 389-397.	3.4	120
434	Functional capacity in rheumatoid arthritis patients: comparison between Spanish and Brazilian sample. <i>Rheumatology International</i> , 2011, 31, 221-226.	3.0	11
435	The <i>PTPN22</i> R263Q polymorphism is a risk factor for rheumatoid arthritis in Caucasian caseâ€“control samples. <i>Arthritis and Rheumatism</i> , 2011, 63, 365-372.	6.7	64
436	Deletion of LCE3C and LCE3B is a susceptibility factor for psoriatic arthritis: A study in Spanish and Italian populations and meta-analysis. <i>Arthritis and Rheumatism</i> , 2011, 63, 1860-1865.	6.7	31
437	A replication study confirms the association of <i>TNFSF4 (OX40L)</i> polymorphisms with systemic sclerosis in a large European cohort. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 638-641.	0.9	63
438	Evidence for <i>PTPN22</i> R620W Polymorphism As the Sole Common Risk Variant for Rheumatoid Arthritis in the 1p13.2 Region. <i>Journal of Rheumatology</i> , 2011, 38, 2290-2296.	2.0	20
439	Subclinical Atherosclerosis in Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2011, 38, 2073-2073.	2.0	1
440	Relapses and Recurrences in Giant Cell Arteritis. <i>Medicine (United States)</i> , 2011, 90, 186-193.	1.0	122
441	The Functional Polymorphism 844 A>G in FcÎ±RI (CD89) Does Not Contribute to Systemic Sclerosis or Rheumatoid Arthritis Susceptibility. <i>Journal of Rheumatology</i> , 2011, 38, 446-449.	2.0	4
442	Association of a non-synonymous functional variant of the ITGAM gene with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2050-2052.	0.9	15
443	Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy. <i>PLoS Genetics</i> , 2011, 7, e1002178.	3.5	201
444	Role of rs1343151 <i>IL23R</i> and rs3790567 <i>IL12RB2</i> Polymorphisms in Biopsy-proven Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2011, 38, 889-892.	2.0	20
445	A Nonsynonymous Functional Variant of the ITGAM Gene Is Not Involved in Biopsy-proven Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2011, 38, 2598-2601.	2.0	4
446	Role of the rs6822844 gene polymorphism at the IL2-IL21 region in biopsy-proven giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S12-6.	0.8	4
447	Giant Cell Arteritis: Epidemiology, Diagnosis, and Management. <i>Current Rheumatology Reports</i> , 2010, 12, 436-442.	4.7	83
448	Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with Gout. <i>Arthritis Care and Research</i> , 2010, 62, 1299-1305.	3.4	44
449	Protection against antiâ€“citrullinated protein antibodyâ€“positive rheumatoid arthritis is predominantly associated with HLAâ€“DRB1*1301: A metaâ€“analysis of HLAâ€“DRB1 associations with antiâ€“citrullinated protein antibodyâ€“positive and antiâ€“citrullinated protein antibodyâ€“negative rheumatoid arthritis in four European populations. <i>Arthritis and Rheumatism</i> . 2010. 62. 1236-1245.	6.7	135
450	Deletion of the late cornified envelope genes, <i>LCE3C</i> and <i>LCE3B</i>, is associated with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 1246-1251.	6.7	26

#	ARTICLE	IF	CITATIONS
451	Identification of the oxidative stress-related gene <i>MSRA</i> as a rheumatoid arthritis susceptibility locus by genome-wide pathway analysis. <i>Arthritis and Rheumatism</i> , 2010, 62, 3183-3190.	6.7	16
452	Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. <i>Nature Genetics</i> , 2010, 42, 426-429.	21.4	351
453	Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF therapy. <i>Annals of the New York Academy of Sciences</i> , 2010, 1193, 153-159.	3.8	125
454	Lack of Association Between TRAF1/C5 Gene Polymorphisms and Biopsy-proven Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2010, 37, 131-135.	2.0	8
455	Influence of IL2RA rs2104286 Polymorphism in the Risk of Biopsy-proven Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2010, 37, 2331-2333.	2.0	3
456	Not losing sight is the issue in GCA management. <i>Nature Reviews Rheumatology</i> , 2010, 6, 440-441.	8.0	3
457	Medical management of polymyalgia rheumatica. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1077-1087.	1.8	16
458	Role of <i>BANK1</i> Gene Polymorphisms in Biopsy-proven Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2010, 37, 1502-1504.	2.0	4
459	Lack of Association Between the rs6920220 (G/A) Polymorphism of the 6q23 Region and Biopsy-proven Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2010, 37, 1020-1023.	2.0	1
460	Lack of Association Between IRF5 Gene Polymorphisms and Biopsy-proven Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2010, 37, 136-140.	2.0	6
461	Functional Variants of Fc Gamma Receptor (FCGR2A) and FCGR3A Are Not Associated with Susceptibility to Systemic Sclerosis in a Large European Study (EUSTAR). <i>Journal of Rheumatology</i> , 2010, 37, 1673-1679.	2.0	9
462	Role of the C8orf13-BLK region in biopsy-proven giant cell arteritis. <i>Human Immunology</i> , 2010, 71, 525-529.	2.4	9
463	Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations. <i>Journal of Autoimmunity</i> , 2010, 34, 155-162.	6.5	123
464	Predictors of positive temporal artery biopsy in patients with giant cell arteritis and polymyalgia rheumatica (comment on the article by MarÃ©t al.). <i>European Journal of Internal Medicine</i> , 2010, 21, 51.	2.2	6
465	Influence of <i>CD40</i> rs1883832 Polymorphism in Susceptibility to and Clinical Manifestations of Biopsy-proven Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2010, 37, 2076-2080.	2.0	19
466	Role of carotid ultrasonography in the evaluation of cardiovascular risk in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2010, 12, 409.	3.5	0
467	A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2010, 12, R71.	3.5	71
468	Association between IL-18 gene polymorphisms and biopsy-proven giant cell arteritis. <i>Arthritis Research and Therapy</i> , 2010, 12, R51.	3.5	25

#	ARTICLE	IF	CITATIONS
469	Lack of association between IFNGR1 gene polymorphisms and biopsy-proven giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, 31-4.	0.8	6
470	Lack of Association Between <i>STAT4</i> Gene Polymorphism and Biopsy-proven Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2009, 36, 1021-1025.	2.0	8
471	C-Reactive Protein Gene Polymorphisms in Biopsy-proven Giant Cell Arteritis from Northwestern Spain. <i>Journal of Rheumatology</i> , 2009, 36, 341-346.	2.0	9
472	Identification of a new putative functional IL18 gene variant through an association study in systemic lupus erythematosus. <i>Human Molecular Genetics</i> , 2009, 18, 3739-3748.	2.9	54
473	Association Between Toll-like Receptor 4 Gene Polymorphism and Biopsy-proven Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2009, 36, 1501-1506.	2.0	36
474	Carotid Intima-Media Thickness Predicts the Development of Cardiovascular Events in Patients with Rheumatoid Arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2009, 38, 366-371.	3.4	211
475	Asymptomatic Hyperuricemia and Serum Uric Acid Concentration Correlate with Subclinical Atherosclerosis in Psoriatic Arthritis Patients Without Clinically Evident Cardiovascular Disease 11 Drs. Gonzalez-Gay, Gonzalez-Juanatey, and Llorca contributed equally to this study.. <i>Seminars in Arthritis and Rheumatism</i> , 2009, 39, 157-162.	3.4	52
476	Study of functional variants of the <i>BANK1</i> gene in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 372-379.	6.7	50
477	Epidemiology of giant cell arteritis and polymyalgia rheumatica. <i>Arthritis and Rheumatism</i> , 2009, 61, 1454-1461.	6.7	460
478	Role of asymptomatic hyperuricemia and serum uric acid levels in the pathogenesis of subclinical atherosclerosis in psoriatic arthritis: Comment on the article by Chen et al. <i>Arthritis and Rheumatism</i> , 2009, 61, 856-857.	6.7	4
479	Prevalence of hepatitis C serum antibody in autoimmune diseases. <i>Journal of Autoimmunity</i> , 2009, 32, 261-266.	6.5	65
480	Strokes at Time of Disease Diagnosis in a Series of 287 Patients With Biopsy-Proven Giant Cell Arteritis. <i>Medicine (United States)</i> , 2009, 88, 227-235.	1.0	189
481	The High Prevalence of Subclinical Atherosclerosis in Patients With Ankylosing Spondylitis Without Clinically Evident Cardiovascular Disease. <i>Medicine (United States)</i> , 2009, 88, 358-365.	1.0	121
482	Association of <i>STAT4</i> with rheumatoid arthritis: A replication study in three European populations. <i>Arthritis and Rheumatism</i> , 2008, 58, 1974-1980.	6.7	93
483	Contribution of HLA-DRB1 shared epitope alleles and chronic inflammation to the increased incidence of cardiovascular disease in rheumatoid arthritis: Comment on the article by Farragher et al. <i>Arthritis and Rheumatism</i> , 2008, 58, 2584-2584.	6.7	4
484	Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor α blocker therapy. <i>Arthritis and Rheumatism</i> , 2008, 59, 1821-1824.	6.7	98
485	The Erythrocyte Sedimentation Rate Is Associated with the Development of Visual Complications in Biopsy-Proven Giant Cell Arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 38, 116-123.	3.4	51
486	Endothelial Dysfunction, Carotid Intima-Media Thickness, and Accelerated Atherosclerosis in Rheumatoid Arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 38, 67-70.	3.4	96

#	ARTICLE	IF	CITATIONS
487	Carotid intima-media thickness and endothelial function: useful surrogate markers for establishing cardiovascular risk in patients with inflammatory rheumatic disease. <i>Arthritis Research and Therapy</i> , 2008, 10, 403.	3.5	7
488	Giant left atrial myxoma mimicking severe mitral valve stenosis. <i>International Journal of Cardiology</i> , 2008, 127, e110-e112.	1.7	8
489	CXCL5 Gene Polymorphism Association with Diabetes Mellitus. <i>Molecular Diagnosis and Therapy</i> , 2008, 12, 391-394.	3.8	13
490	The clinical implication of cervical interspinous bursitis in the diagnosis of polymyalgia rheumatica. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 733-734.	0.9	15
491	Audiovestibular Manifestations in Patients With Limited Systemic Sclerosis and Centromere Protein-B (CENP-B) Antibodies. <i>Medicine (United States)</i> , 2008, 87, 131-141.	1.0	38
492	A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus. <i>Human Molecular Genetics</i> , 2008, 18, 569-579.	2.9	106
493	Benign Paroxysmal Positional Vertigo and Clinical Test of Sensory Interaction and Balance in Systemic Sclerosis. <i>Otology and Neurotology</i> , 2008, 29, 1155-1161.	1.3	27
494	Systemic Sclerosis in Northwestern Spain. <i>Medicine (United States)</i> , 2008, 87, 272-280.	1.0	109
495	Association of CD24 gene polymorphisms with susceptibility to biopsy-proven giant cell arteritis. <i>Journal of Rheumatology</i> , 2008, 35, 850-4.	2.0	23
496	CD4+CD25+ T Cell-Dependent Inhibition of Autoimmunity in Transgenic Mice Overexpressing Human Bcl-2 in T Lymphocytes. <i>Journal of Immunology</i> , 2007, 178, 2778-2786.	0.8	15
497	Giant Cell Arteritis in Northwestern Spain. <i>Medicine (United States)</i> , 2007, 86, 61-68.	1.0	168
498	Molecular screening and association study of IL15 gene polymorphisms in rheumatoid arthritis. <i>Cytokine</i> , 2007, 38, 84-89.	3.2	10
499	Two coincidental neurological complications as a presenting form of infectious endocarditis. <i>International Journal of Cardiology</i> , 2007, 117, e107-e108.	1.7	0
500	HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007, 57, 125-132.	6.7	312
501	Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. <i>Arthritis and Rheumatism</i> , 2007, 57, 287-293.	6.7	185
502	Glucocorticoid-related cardiovascular and cerebrovascular events in rheumatic diseases: Myth or reality?. <i>Arthritis and Rheumatism</i> , 2007, 57, 191-192.	6.7	9
503	Association of a CD24 gene polymorphism with susceptibility to systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007, 56, 3080-3086.	6.7	47
504	High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. <i>Arthritis and Rheumatism</i> , 2007, 57, 1074-1080.	6.7	220

#	ARTICLE	IF	CITATIONS
505	<i>HO-1</i> promoter polymorphism associated with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 3953-3958.	6.7	68
506	Atherosclerosis in patients with biopsy-proven giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2007, 57, 1481-1486.	6.7	43
507	Persistent Chronic Inflammation Contributes to the Development of Cancer in Patients with Rheumatoid Arthritis from a Defined Population of Northwestern Spain. <i>Seminars in Arthritis and Rheumatism</i> , 2007, 37, 31-38.	3.4	32
508	Cancer in Biopsy-Proven Giant Cell Arteritis. A Population-Based Study. <i>Seminars in Arthritis and Rheumatism</i> , 2007, 37, 156-163.	3.4	35
509	Late onset undifferentiated spondyloarthritis presenting with polymyalgia rheumatica features: description of seven cases. <i>Rheumatology International</i> , 2007, 27, 927-933.	3.0	40
510	Influence of interleukin 10 promoter polymorphisms in susceptibility to giant cell arteritis in Northwestern Spain. <i>Journal of Rheumatology</i> , 2007, 34, 1535-9.	2.0	20
511	Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis. <i>Arthritis Research and Therapy</i> , 2006, 8, R109.	3.5	47
512	Giant Cell Arteritis and Polymyalgia Rheumatica. <i>Drugs and Aging</i> , 2006, 23, 627-649.	2.7	34
513	Cardiovascular disease in rheumatoid arthritis. <i>Biomedicine and Pharmacotherapy</i> , 2006, 60, 673-677.	5.6	43
514	Septic discitis as initial manifestation of streptococcus bovis endocarditis. <i>International Journal of Cardiology</i> , 2006, 108, 128-129.	1.7	5
515	Austrian syndrome: Report of two new cases and literature review. <i>International Journal of Cardiology</i> , 2006, 108, 273-275.	1.7	25
516	Aplasia Cutis Congenita in a Defined Population from Northwest Spain. <i>Pediatric Dermatology</i> , 2006, 23, 528-532.	0.9	35
517	Study of six X-linked tetranucleotide microsatellites: population data from five Spanish regions. <i>International Journal of Legal Medicine</i> , 2006, 120, 147-150.	2.2	20
518	Giant cell arteritis: Diagnosis and therapeutic management. <i>Current Rheumatology Reports</i> , 2006, 8, 299-302.	4.7	21
519	Multiple parosteal lipoma associated to polyarthritis. <i>Joint Bone Spine</i> , 2006, 73, 202-204.	1.6	8
520	Lack of Echocardiographic and Doppler Abnormalities in Psoriatic Arthritis Patients Without Clinically Evident Cardiovascular Disease or Classic Atherosclerosis Risk Factors. <i>Seminars in Arthritis and Rheumatism</i> , 2006, 35, 333-339.	3.4	37
521	Localized Vasculitis of the Gastrointestinal Tract. <i>Seminars in Arthritis and Rheumatism</i> , 2006, 35, 403-406.	3.4	21
522	Effect of anti-tumor necrosis factor therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 55, 150-153.	6.7	86

#	ARTICLE	IF	CITATIONS
523	Analysis of IRF5 gene functional polymorphisms in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 3815-3819.	6.7	53
524	Silent Giant Cell Arteritis. <i>Southern Medical Journal</i> , 2006, 99, 1204-1205.	0.7	3
525	Association between functional haplotypes of vascular endothelial growth factor and renal complications in Henoch-Schönlein purpura. <i>Journal of Rheumatology</i> , 2006, 33, 69-73.	2.0	31
526	Giant Cell Arteritis. <i>Medicine (United States)</i> , 2005, 84, 277-290.	1.0	149
527	Pacemaker infection due to <i>Aspergillus</i> : report of two cases and literature review. <i>Clinical Cardiology</i> , 2005, 28, 36-38.	1.8	8
528	Anomalies of vertebrae and ribs: Jarcho Levin syndrome. Description of a case and literature review. <i>Joint Bone Spine</i> , 2005, 72, 275-277.	1.6	24
529	Rheumatoid Arthritis: A Disease Associated with Accelerated Atherogenesis. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 8-17.	3.4	282
530	The Increased Risk of Ventricular Diastolic Dysfunction and Congestive Heart Failure in Patients with Rheumatoid Arthritis Is Independent of the Duration of the Disease. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 132-133.	3.4	13
531	Controversies on the Use of Corticosteroid Therapy in Children with Henoch-Schönlein Purpura. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 135-137.	3.4	14
532	Association of a functional single nucleotide polymorphism of <i>PTPN22</i> , encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2005, 52, 219-224.	6.7	275
533	Magnetic resonance imaging in optic neuritis due to giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2005, 53, 313-314.	6.7	8
534	Supraclavicular pulsatile mass as presenting sign of brachiocephalic trunk aneurysm in the long-term followup of giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2005, 53, 475-476.	6.7	6
535	Calcium pyrophosphate deposition disease mimicking polymyalgia rheumatica: A prospective followup study of predictive factors for this condition in patients presenting with polymyalgia symptoms. <i>Arthritis and Rheumatism</i> , 2005, 53, 931-938.	6.7	52
536	Two Polymorphisms in the Epithelial Cell-Derived Neutrophil-Activating Peptide (ENA-78) Gene. <i>Disease Markers</i> , 2005, 21, 75-77.	1.3	6
537	Human leukocyte antigen-DQB1 and -DRB1 associations in patients with idiopathic sudden sensorineural hearing loss from a defined population of Northwest Spain. <i>Acta Oto-Laryngologica</i> , 2005, 125, 1277-1282.	0.9	18
538	Giant Cell Arteritis. <i>Medicine (United States)</i> , 2005, 84, 269-276.	1.0	256
539	Rheumatoid arthritis and anti-TNF therapy. <i>Atherosclerosis</i> , 2005, 181, 209.	0.8	2
540	Interleukin 12 (IL12B) and Interleukin 12 Receptor (IL12RB1) Gene Polymorphisms in Rheumatoid Arthritis. <i>Human Immunology</i> , 2005, 66, 710-714.	2.4	32

#	ARTICLE	IF	CITATIONS
541	Analysis of a Functional BTNL2 Polymorphism in Type 1 Diabetes, Rheumatoid Arthritis, and Systemic Lupus Erythematosus. <i>Human Immunology</i> , 2005, 66, 1235-1241.	2.4	70
542	The diagnosis and management of patients with giant cell arteritis. <i>Journal of Rheumatology</i> , 2005, 32, 1186-8.	2.0	51
543	High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 1219-23.	2.0	187
544	A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis. <i>Journal of Rheumatology</i> , 2005, 32, 1737-41.	2.0	61
545	Rheumatoid Arthritis and Accelerated Atherogenesis. <i>Circulation</i> , 2004, 109, e328; author reply e328.	1.6	5
546	Aortic Aneurysm and Dissection in Patients With Biopsy-Proven Giant Cell Arteritis From Northwestern Spain. <i>Medicine (United States)</i> , 2004, 83, 335-341.	1.0	200
547	Giant Cell Arteritis: A New Association with Benign Paroxysmal Positional Vertigo. <i>Laryngoscope</i> , 2004, 114, 1420-1425.	2.0	39
548	Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 33, 289-293.	3.4	170
549	The pros and cons of intravenous immunoglobulin treatment in autoimmune nephropathy. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 34, 573-574.	3.4	3
550	Echocardiographic and Doppler findings in long-term treated rheumatoid arthritis patients without clinically evident cardiovascular disease. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 33, 231-238.	3.4	102
551	Endothelial dysfunction in rheumatoid arthritis: influence of HLA-DRB1 alleles. <i>Autoimmunity Reviews</i> , 2004, 3, 301-304.	5.8	31
552	Giant cell arteritis without clinically evident vascular involvement in a defined population. <i>Arthritis and Rheumatism</i> , 2004, 51, 274-277.	6.7	43
553	Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor \pm antibody. <i>Arthritis and Rheumatism</i> , 2004, 51, 447-450.	6.7	191
554	Fever in biopsy-proven giant cell arteritis: Clinical implications in a defined population. <i>Arthritis and Rheumatism</i> , 2004, 51, 652-655.	6.7	41
555	Long-term rheumatoid arthritis and endothelial dysfunction. <i>Atherosclerosis</i> , 2004, 176, 197-198.	0.8	4
556	Influence of Traditional Risk Factors of Atherosclerosis in the Development of Severe Ischemic Complications in Giant Cell Arteritis. <i>Medicine (United States)</i> , 2004, 83, 342-347.	1.0	157
557	Osteitis pubis after Marshallâ€™Marchettiâ€™Krantz urethropexy. <i>Joint Bone Spine</i> , 2003, 70, 61-63.	1.6	18
558	Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. <i>Seminars in Arthritis and Rheumatism</i> , 2003, 33, 38-48.	3.4	146

#	ARTICLE	IF	CITATIONS
559	The epidemiology of the primary systemic vasculitides in northwest Spain: Implications of the Chapel Hill Consensus Conference definitions. <i>Arthritis and Rheumatism</i> , 2003, 49, 388-393.	6.7	190
560	Neovascularization around the optic nerve in giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2003, 49, 737-738.	6.7	8
561	Fatigue fractures suggesting clinical monarthritis. <i>Arthritis and Rheumatism</i> , 2003, 49, 741-744.	6.7	2
562	Potential role of mitral valve strands on stroke recurrence in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003, 49, 866-867.	6.7	6
563	HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. <i>American Journal of Medicine</i> , 2003, 114, 647-652.	1.5	160
564	Audiovestibular Manifestations in Giant Cell Arteritis. <i>Medicine (United States)</i> , 2003, 82, 13-26.	1.0	81
565	Increased Prevalence of Severe Subclinical Atherosclerotic Findings in Long-Term Treated Rheumatoid Arthritis Patients Without Clinically Evident Atherosclerotic Disease. <i>Medicine (United States)</i> , 2003, 82, 407-413.	1.0	207
566	Re: Autoimmunity in sudden sensorineural hearing loss by Cadoni et al. <i>Acta Oto-Laryngologica</i> , 2003, 123, 1115-1115.	0.9	2
567	Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2002, 31, 355-360.	3.4	164
568	Tubulointerstitial nephritis and uveitis syndrome in Southern Spain. <i>Seminars in Arthritis and Rheumatism</i> , 2002, 32, 125-129.	3.4	26
569	Henoch-Schönlein purpura in children and adults: Clinical differences in a defined population. <i>Seminars in Arthritis and Rheumatism</i> , 2002, 32, 149-156.	3.4	170
570	Systemic vasculitides. <i>Best Practice and Research in Clinical Rheumatology</i> , 2002, 16, 833-845.	3.3	15
571	Orlistat-induced cutaneous leukocytoclastic vasculitis. <i>Arthritis and Rheumatism</i> , 2002, 47, 567-567.	6.7	18
572	HLA-B35 association with nephritis in Henoch-Schönlein purpura. <i>Journal of Rheumatology</i> , 2002, 29, 948-9.	2.0	31
573	Genetic epidemiology. Giant cell arteritis and polymyalgia rheumatica. <i>Arthritis Research</i> , 2001, 3, 154.	2.0	61
574	EPIDEMIOLOGY OF THE VASCULITIDES. <i>Rheumatic Disease Clinics of North America</i> , 2001, 27, 729-749.	1.9	181
575	Biopsy-negative giant cell arteritis: Clinical spectrum and predictive factors for positive temporal artery biopsy. <i>Seminars in Arthritis and Rheumatism</i> , 2001, 30, 249-256.	3.4	193
576	Rheumatic Manifestations of Infective Endocarditis in Non-Addicts. <i>Medicine (United States)</i> , 2001, 80, 9-19.	1.0	89

#	ARTICLE	IF	CITATIONS
577	Henoch-Schönlein Purpura in Children from Northwestern Spain. <i>Medicine (United States)</i> , 2001, 80, 279-290.	1.0	235
578	Erythema nodosum: Etiologic and predictive factors in a defined population. <i>Arthritis and Rheumatism</i> , 2000, 43, 584.	6.7	123
579	Anterior crural neuralgia as a presenting manifestation of lymphocele. <i>Arthritis and Rheumatism</i> , 2000, 43, 1183.	6.7	2
580	Trends in the inflammatory response in biopsy-proven giant cell arteritis: Comment on the article by Cid et al, and the letters by Neshet and Sonnenblick and Liozon et al. <i>Arthritis and Rheumatism</i> , 2000, 43, 1427-1428.	6.7	8
581	Association of giant cell arteritis and polymyalgia rheumatica with different tumor necrosis factor microsatellite polymorphisms. <i>Arthritis and Rheumatism</i> , 2000, 43, 1749-1755.	6.7	89
582	Uncommon arthritis as presenting manifestation of silent Crohn's disease. <i>Joint Bone Spine</i> , 2000, 67, 553-554.	1.6	1
583	Penicillamine-Induced Crescentic Glomerulonephritis in a Patient with Scleroderma. <i>Nephron</i> , 2000, 84, 101-102.	1.8	9
584	Visual Manifestations of Giant Cell Arteritis: Trends and Clinical Spectrum in 161 Patients. <i>Medicine (United States)</i> , 2000, 79, 283-292.	1.0	333
585	HLA-DRB1*04 may be a marker of severity in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2000, 59, 574a-574.	0.9	10
586	Comparative clinical and epidemiological study of hypersensitivity vasculitis versus Henoch-Schönlein purpura in adults. <i>Seminars in Arthritis and Rheumatism</i> , 1999, 28, 404-412.	3.4	113
587	Can HLA-DR explain the varying frequency of synovitis in polymyalgia rheumatica? Comment on the article by Salvarani et al. <i>Arthritis and Rheumatism</i> , 1999, 42, 1561-1562.	6.7	0
588	Systemic Vasculitis in Adults in Northwestern Spain, 1988-1997: Clinical and Epidemiologic Aspects. <i>Medicine (United States)</i> , 1999, 78, 292-308.	1.0	191
589	Arthritis in the right great toe as the clinical presentation of tuberculosis. <i>Arthritis and Rheumatism</i> , 1998, 41, 374-375.	6.7	12
590	Cutaneous vasculitis as a paraneoplastic syndrome in adults. <i>Arthritis and Rheumatism</i> , 1998, 41, 1133-1135.	6.7	65
591	Permanent visual loss and cerebrovascular accidents in giant cell arteritis: Predictors and response to treatment. <i>Arthritis and Rheumatism</i> , 1998, 41, 1497-1504.	6.7	367
592	Successful Response to Captopril in Severe Nephrotic Syndrome Secondary to Lupus Nephritis. <i>Nephron</i> , 1998, 80, 353-354.	1.8	1
593	Polymyalgia Rheumatica vs Rheumatoid Arthritis in the Elderly. <i>Archives of Internal Medicine</i> , 1997, 157, 2016.	3.8	1
594	Polymicrobial Prepatellar Septic Bursitis Caused by <i>Brucella Abortus</i> and <i>Streptococcus Agalactiae</i> . <i>Journal of Clinical Rheumatology</i> , 1997, 3, 120.	0.9	2

#	ARTICLE	IF	CITATIONS
595	Risk Factors and Predictive Models of Giant Cell Arteritis in Polymyalgia Rheumatica. American Journal of Medicine, 1997, 102, 331-336.	1.5	71
596	Henoch-Schönlein purpura in adulthood and childhood. Two different expressions of the same syndrome. Arthritis and Rheumatism, 1997, 40, 859-864.	6.7	365
597	Human leukocyte antigen-DRB1*1502 (DR2Dw12) transgene reduces incidence and severity of arthritis in mice. Human Immunology, 1996, 50, 54-60.	2.4	43
598	Henoch-Schönlein purpura with hemorrhagic ascites and intestinal serositis. Gastrointestinal Endoscopy, 1996, 44, 624-625.	1.0	8
599	H2-A polymorphism contributes to H2-E*2-mediated protection in collagen-induced arthritis. Immunogenetics, 1996, 44, 377-384.	2.4	5
600	Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine. Arthritis and Rheumatism, 1996, 39, 1016-1020.	6.7	44
601	Giant cell arteritis and amyloidosis: comment on the article by Salvarani et al. Arthritis and Rheumatism, 1996, 39, 1073-1074.	6.7	0
602	Letter to the editor. Low-dose corticosteroids and blindness in giant cell arteritis. British Journal of Rheumatology, 1996, 35, 702-3.	2.3	1
603	Polymorphism of the MHC class II E* gene determines the protection against collagen-induced arthritis. Immunogenetics, 1995, 42, 35-40.	2.4	46
604	Could HLA-DRB1 be the protective locus in rheumatoid arthritis?. Trends in Immunology, 1995, 16, 274-278.	7.5	183
605	Optic Neuritis following Treatment with Isoniazid in a Hemodialyzed Patient. Nephron, 1993, 63, 360-360.	1.8	11
606	Giant cell arteritis in Mediterranean countries: Comment on the article by Salvarani et al. Arthritis and Rheumatism, 1992, 35, 1249-1250.	6.7	9
607	Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype. Clinical and Experimental Rheumatology, 0, , .	0.8	1
608	Apolipoprotein C3 and beta-cell dysfunction are linked in patients with systemic lupus erythematosus. Clinical and Experimental Rheumatology, 0, , .	0.8	1
609	Alpha-Klotho protein in systemic lupus erythematosus. Clinical and Experimental Rheumatology, 0, , .	0.8	2
610	Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy. Clinical and Experimental Rheumatology, 0, , .	0.8	1
611	Amylin serum levels are upregulated in patients with systemic lupus erythematosus. Clinical and Experimental Rheumatology, 0, , .	0.8	1
612	Obesity and response to biological therapy in rheumatoid arthritis: the role of body mass index and adipose tissue cytokines. Clinical and Experimental Rheumatology, 0, , .	0.8	3